Biocartis Group NV announced that Biocartis and Genomic Health, Inc. have agreed to terminate their collaboration, which was focused on the development of the Oncotype DX Breast Recurrence Score® test on Biocartis' molecular diagnostics platform Idylla. As a result of COVID-19, the project had been suspended earlier during 2020, with the project plan and timing under evaluation. The decision to now terminate the collaboration was driven by the uncertain timing of a product market release because of the pandemic and a decision by Exact Sciences to shift priorities to other initiatives.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.29 EUR | +1.05% | -.--% | -.--% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-.--% | 29.18M | |
+73.22% | 12.36B | |
-21.27% | 7.83B | |
+15.66% | 7.21B | |
+4.77% | 5.97B | |
+11.77% | 5.14B | |
+29.65% | 4.43B | |
-18.81% | 3.9B | |
-41.57% | 2.2B | |
+1.24% | 2.02B |
- Stock Market
- Equities
- BCART Stock
- News Biocartis Group NV
- Biocartis Group NV and Biocartis and Genomic Health, Inc. Agree to End Collaboration Due to Changed Market Circumstances